Medpace Holdings Inc. logo

Medpace Holdings Inc. (MEDP)

Market Closed
3 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
450. 81
+5.23
+1.17%
$
12.89B Market Cap
35.12 P/E Ratio
- Div Yield
240,034 Volume
8.64 Eps
$ 445.59
Previous Close
Add Transaction
Day Range
434.38 451.68
Year Range
293.2 628.92
Want to track MEDP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

MEDP closed today higher at $450.81, an increase of 1.17% from yesterday's close, completing a monthly increase of 0.98% or $4.39. Over the past 12 months, MEDP stock lost -19.3%.
MEDP is not paying dividends to its shareholders.
The last earnings report, released on Apr 27, 2026, missed the consensus estimates by -3.92%. On average, the company has fell short of earnings expectations by -1.03%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

MEDP Chart

People also search for

Palo Alto Networks, Inc.
$ 280.43
-5.64%
CrowdStrike Holdings, Inc.
$ 747.61
-2.78%
HON
Honeywell International Inc.
$ 223.26
-5.09%
Honeywell International Inc.
$ 200.99
-0.5%
Booking Holdings Inc.
$ 164.78
-1.45%
Medpace (MEDP) Stock Slides as Market Rises: Facts to Know Before You Trade

Medpace (MEDP) Stock Slides as Market Rises: Facts to Know Before You Trade

Medpace (MEDP) closed at $445.59 in the latest trading session, marking a -1.3% move from the prior day.

Zacks | 23 hours ago
LH or MEDP: Which Is the Better Value Stock Right Now?

LH or MEDP: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical Services sector might want to consider either Labcorp Holdings (LH) or Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks | 1 week ago
Medpace: Off The Pace Here Amidst Continued Booking Softness

Medpace: Off The Pace Here Amidst Continued Booking Softness

Medpace's shares have sharply declined following a disappointing quarterly earnings report. A soft start to the year raises concerns about Medpace's near-term growth trajectory and operational momentum. The earnings miss may prompt investors to reassess MEDP's valuation and forward expectations.

Seekingalpha | 1 month ago

Medpace Holdings Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
Bridgewater Associates LP
Bridgewater Associates LP Bridgewater Associates LP
41,135 $20.97M $18.54M -$2.42M -11.56%
SkyOak Wealth
SkyOak Wealth SkyOak Wealth LLC
600 $288,114 $270,486 -$17,625 -6.12%
Keebeck Wealth Management
Keebeck Wealth Management Keebeck Wealth Management LLC
1,314 $441,461.93 $592,364.34 $150,908.98 34.18%
LCG
Legacy Capital Group California Inc. Legacy Capital Group California, Inc.
653 $366,757.28 $294,378.93 -$72,375.09 -19.73%
AS
Alexandra Stickelman Root Financial Partners, LLC
122 $62,529.51 $54,998.82 -$7,530.08 -12.04%

Medpace Holdings Inc. (MEDP) FAQ

What is the stock price today?

The current price is $450.81.

On which exchange is it traded?

Medpace Holdings Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is MEDP.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 12.89B.

Has Medpace Holdings Inc. ever had a stock split?

No, there has never been a stock split.

Medpace Holdings Inc. Profile

Professional Services Industry
Industrials Sector
August James Troendle CEO
NASDAQ (NGS) Exchange
58506Q109 CUSIP
US Country
5,900 Employees
- Last Dividend
- Last Split
11 Aug 2016 IPO Date

Overview

Medpace Holdings, Inc., founded in 1992 and headquartered in Cincinnati, Ohio, is a key player in the provision of comprehensive clinical research services for the development of drugs and medical devices. Spanning its operations across North America, Europe, and Asia, the company supports pharmaceutical, biotechnology, and medical device industries through the entire clinical development process, from Phase I to Phase IV, across a wide range of therapeutic areas. Its aim is to facilitate the journey of bringing new and innovative treatments to market efficiently and effectively.

Products and Services

  • Development Plan Design: Crafting bespoke development strategies addressing specific therapeutic area requirements and regulatory landscapes to streamline the development process from concept to market.
  • Coordinated Central Laboratory: Offering centralized lab services that reduce logistical complexities, enhance data quality, and streamline sample management across global trial sites.
  • Project Management: Delivering comprehensive project oversight to ensure milestones are met on time and within budget while maintaining adherence to regulatory standards.
  • Regulatory Affairs: Providing expertise in navigating the complex regulatory environment to facilitate timely approval from regulatory bodies.
  • Clinical Monitoring: Ensuring the integrity of clinical trial data through close site monitoring, including site selection, training, and ongoing assessment for adherence to protocols.
  • Data Management and Analysis: Implementing rigorous processes for data collection, validation, and analysis to support statistical significance and findings of clinical trials.
  • Pharmacovigilance: Monitoring and managing the safety profile of drugs through all phases of clinical trials to ensure patient safety and regulatory compliance.
  • New Drug Application Submissions: Assisting in the preparation and submission of documentation required for the approval of new drugs, ensuring accuracy and regulatory compliance.
  • Post-Marketing Clinical Support: Offering services to monitor a drug's performance and safety after it has been approved and is in the market to fulfill post-marketing requirements and commitments.
  • Bio-Analytical Laboratory Services: Providing state-of-the-art laboratory services to support the analysis of biological samples, which is crucial for understanding the pharmacokinetics and pharmacodynamics of a drug.
  • Clinical Human Pharmacology: Conducting early phase clinical trials, including first-in-human studies, to assess the safety, tolerability, and pharmacokinetics of a drug.
  • Imaging Services: Utilizing advanced imaging technologies to enhance understanding of a drug's mechanism of action and contribute to endpoint assessments in clinical trials.
  • Electrocardiography (ECG) Reading Support: Offering expert ECG analysis to detect potential cardiac risks in clinical trial participants, enhancing patient safety throughout the trial process.

Contact Information

Address: 5375 Medpace Way
Phone: 513 579 9911